NCT06166836 - a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Solid Tumor

Interventions

DRUG

D1553

D1553 orally taken，600mg twice a day

DRUG

IN10018（Ifebemtinib）

IN10018 orally taken once daily at approximately the same time each day

Trial Locations (10)

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

First Affiliated Hospital of Bengbu Medical College, Bengbu

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

First Affiliated Hospital of Gannan Medical University, Ganzhou

RECRUITING

General Hospital Of Eastern Theater Command, Nanjing

RECRUITING

Renmin Hospital of Wuhan University, Wuhan

RECRUITING

Xuzhou Central Hospital, Xuzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The first Affiliated Hospital of Zhengzhou University, Zhengzhou